Cost-effectiveness analysis of empagliflozin as an add-on to the standard of care for chronic kidney disease management in the Philippines
Empagliflozin is cost-saving and provides utility benefits when added to SoC among patients with CKD. This finding holds significant value for patients with CKD, regardless of diabetes status.
Authors
- Arlene Cabotaje Crisostomo (ORCID: https://orcid.org/0009-0005-7225-9315)
- Elaine C Cunanan (ORCID: https://orcid.org/0000-0002-4049-7918)
- Amor Patrice Estabillo
- Danny Yu (ORCID: https://orcid.org/0000-0002-8997-8560)
- Dianne Danielle Tan-Lim
- Jennifer Ivy Togonon-Leaño
- Miharu Jay Kimwell
- Patrick James Encarnacion
- Mary Joy Taneo (ORCID: https://orcid.org/0000-0003-4454-8070)
- Maria Rhodora De Lara-Valenzona
- Marizel Mallari-Catungal
- Anthony Russell Villanueva
- Richard Henry Perlas Tiongco II
- Precious Juzenda Montilla
- Christianne Jade Gonzales
- Donnah de Leon
Institutions
- University of Santo Tomas Hospital (PH)
- Angeles University Foundation (PH)
- University of Perpetual Help System DALTA (PH)
- Davao Doctors Hospital (PH)
- St. Luke's Medical Center (PH)
- Boehringer Ingelheim (Philippines) (PH)
- Chang Hua Hospital (TW)
- National Kidney and Transplant Institute (PH)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2025-12-24
- DOI
- https://doi.org/10.1080/13696998.2025.2602361
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00